Yu Wei, Zhou Kai, Guo Lihua, Ji Jinru, Niu Tianshui, Xiao Tingting, Shen Ping, Xiao Yonghong
State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang UniversityHangzhou, China.
Department of Infectious Diseases, Zhejiang Provincial People's HospitalHangzhou, China.
Front Cell Infect Microbiol. 2017 Jun 16;7:246. doi: 10.3389/fcimb.2017.00246. eCollection 2017.
The emergence of carbapenem-resistant , especially , has become a major concern in clinic settings. Combination therapy is gaining momentum to counter the secondary resistance and potential suboptimal efficacy of monotherapy. The aim of this study was to evaluate the bactericidal effect of fosfomycin (FM), amikacin (AMK), or colistin (COL) alone and combinations against KPC2-producing using dynamic model by simulating human pharmacokinetics . The Pharmacokinetics Auto Simulation System 400 system was employed to simulate different dosing regimens of FM, AMK, and COL alone and combination. Bacterial growth recovery time (RT) and the area between the control growth and antibacterial killing curves (IE) were used as unbiased and comprehensive means for determining the antimicrobial effect. We observed that COL alone was much pronounced than FM or AMK against KPC-Kp. IE of FM (8 g every 8 h) plus AMK (15 mg/kg once-daily) and FM (8 g every 8 h) plus COL (75,000 IU/kg every 12 h) were higher (>170 and >200 LogCFU/mL·h, respectively) than that of monotherapies against sensitive strains. Of note, the rate of resistance was lower when using the combination of FM (8 g every 8 h) plus COL (75,000 IU/kg every 12 h) than using COL (75,000 IU/kg every 12 h) alone. The combination of FM (8 g every 8 h) plus AMK (15 mg/kg once-daily) and FM (8 g every 8 h) plus COL (75,000 IU/kg every 12 h) were effective at maximizing bacterial killing and suppressing emergence of resistance.
碳青霉烯类耐药菌的出现,尤其是[具体细菌名称未给出],已成为临床环境中的一个主要关注点。联合治疗正逐渐兴起,以应对单药治疗的继发性耐药和潜在的疗效欠佳问题。本研究的目的是通过模拟人体药代动力学,使用动态模型评估单独使用磷霉素(FM)、阿米卡星(AMK)或黏菌素(COL)以及它们的联合用药对产KPC2的[细菌名称未给出]的杀菌效果。使用药代动力学自动模拟系统400系统来模拟FM、AMK和COL单独及联合使用的不同给药方案。细菌生长恢复时间(RT)以及对照生长曲线和抗菌杀灭曲线之间的面积(IE)被用作确定抗菌效果的无偏且全面的指标。我们观察到,单独使用COL对产KPC的肺炎克雷伯菌(KPC-Kp)的作用比FM或AMK更为显著。FM(每8小时8克)加AMK(每日一次15毫克/千克)和FM(每8小时8克)加COL(每12小时75,000国际单位/千克)的IE高于针对敏感菌株的单药治疗(分别>170和>200 LogCFU/mL·h)。值得注意的是,使用FM(每8小时8克)加COL(每12小时75,000国际单位/千克)联合用药时的耐药率低于单独使用COL(每12小时75,000国际单位/千克)。FM(每8小时8克)加AMK(每日一次15毫克/千克)和FM(每8小时8克)加COL(每12小时75,000国际单位/千克)的联合用药在最大化细菌杀灭和抑制耐药性出现方面是有效的。